Bayer takes control of Loxo duo as Lilly closes takeoverBayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the Share XBayer takes control of Loxo duo as Lilly closes takeoverhttps://pharmaphorum.com/news/bayer-control-loxo-duo-lilly-takeover/
Lilly further boosts cancer pipeline with $8bn Loxo acquisitionIn the second big M&A deal of the year following BMS’s acquisition of Celgene, Eli Lilly has announced Share XLilly further boosts cancer pipeline with $8bn Loxo acquisitionhttps://pharmaphorum.com/news/lilly-further-boosts-cancer-pipeline-with-8bn-loxo-acquisition/
Bayer/Loxo drug approved in cancers with certain mutationThe FDA has approved Bayer and Loxo’s Vitrakvi (larotrectinib) for adults and children whose cancers have a specific Share XBayer/Loxo drug approved in cancers with certain mutationhttps://pharmaphorum.com/news/bayer-loxo-drug-approved-in-cancers-with-certain-mutation/
ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint comboBreast cancer has been one area where checkpoint inhibitors have not yet gained traction – but that might Share XASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combohttps://pharmaphorum.com/views-and-analysis/asco-2018-tesaro-checkpoint-combo/
